Improving the therapeutic ratio in non-operable oesophageal cancer
Mené en France sur 259 patients atteints d'un carcinome de l'œsophage de stade I-IVA traité entre 2004 et 2011 (durée médiane de suivi : 25,3 mois), cet essai multicentrique randomisé de phase II/III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité d'une chimiothérapie de type FOLFOX et d'une chimiothérapie par 5-fluorouracile et cisplatine en complément d'une radiothérapie
The management of oesophageal cancer has undergone substantial changes in the past two decades, resulting in improved survival and better regional control of the disease. In patients with inoperable oesophageal cancer, the major advance has been the use of cisplatin-based chemoradiotherapy, which has improved survival, but at the cost of increased toxicity. 1 , 2 In the past 10 years, attempts have been made to further improve the survival of these patients by introducing new drugs into the concomit...
The Lancet Oncology , commentaire, 2013